Development and optimization of a continuous flow ester reduction with LiAlH<sub>4</sub> in the synthesis of a key intermediate for a PI3Kδ inhibitor (CPL302415)-Reference-Cited by-同舟云学术

Development and optimization of a continuous flow ester reduction with LiAlH₄ in the synthesis of a key intermediate for a PI3Kδ inhibitor (CPL302415)

Published:2023 Issue:5 Volume:8 Page:1117-1124
ISSN:2058-9883
Container-title:Reaction Chemistry & Engineering
language:en
Short-container-title:React. Chem. Eng.

Author:

Michałek Stanisław¹²^ORCID,Maj Anna M.¹^ORCID,Gurba-Bryśkiewicz Lidia¹^ORCID,Maruszak Wioleta¹^ORCID,Zagozda Marcin¹,Ochal Zbigniew²,Dubiel Krzysztof¹,Wieczorek Maciej¹

Affiliation:

1. Celon Pharma S.A., ul. Marymoncka 15, 05-152 Kazuń Nowy, Poland

2. Faculty of Chemistry, Warsaw University of Technology, ul. Noakowskiego 3, 00-664 Warsaw, Poland

Abstract

Highly productive (11.3 g h−1) continuous flow LAH ester reduction in the synthesis of a new PI3Kδ inhibitor (CPL302415). Comparison of the efficiency and selectivity of various reduction methods (catalytic with stoichiometric and flow with batch).

Funder

Narodowe Centrum Badań i Rozwoju

Publisher

Royal Society of Chemistry (RSC)

Subject

Fluid Flow and Transfer Processes,Process Chemistry and Technology,Chemical Engineering (miscellaneous),Chemistry (miscellaneous),Catalysis

Link

http://pubs.rsc.org/en/content/articlepdf/2023/RE/D2RE00561A

Reference34 articles.

1. Design, Synthesis, and Biological Activity of Pyridopyrimidine Scaffolds as Novel PI3K/mTOR Dual Inhibitors

2. The ubiquitous phosphoinositides

3. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

4. Inhibition of PI3K Signaling Spurs New Therapeutic Opportunities in Inflammatory/Autoimmune Diseases and Hematological Malignancies

5. Discovery of Novel PI3-Kinase δ Specific Inhibitors for the Treatment of Rheumatoid Arthritis: Taming CYP3A4 Time-Dependent Inhibition